BMO Capital Markets' Evan Seigerman discusses the booming biotech sector, highlighting GLP-1 weight-loss drugs' demand. He also points out opportunities in companies like Regeneron and Vertex, emphasizing Vertex's leadership in cystic fibrosis research and upcoming approvals for new treatments.